John Robson
BioOra
8/10Traction
The startup manufactures chimeric antigen receptor (CAR) T-cells that streamline the process from patient blood isolation to CAR T-cell infusion, significantly reducing treatment time and costs. By optimizing each step of the manufacturing process, the company enhances scalability and provides patients with timely access to clinical-grade therapies.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$3.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup manufactures chimeric antigen receptor (CAR) T-cells that streamline the process from patient blood isolation to CAR T-cell infusion, significantly reducing treatment time and costs. By optimizing each step of the manufacturing process, the company enhances scalability and provides patients with timely access to clinical-grade therapies.